Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus
Authors' conclusion
Among Japanese patients with T2D, tirzepatide showed the greatest effectiveness in reducing HbA1c levels and inducing weight loss. The study provides evidence to guide GLP-1RA treatment strategies in Japanese patients with T2D.
Study context
- Population
- Japanese patients with T2D; Randomized controlled trials (RCTs) comparing GLP-1 RAs or GIP/GLP-1 RAs (PubMed, MEDLINE, EMBASE, Cochrane Library to July 2023)18 RCTs
- Comparison
- GIP/GLP-1 RA vs GLP-1 RAs
- Outcome
- Reduction in HbA1c and body weight
Methodological detailsindirect comparison
- Indirect comparison
Pooled result
As reported in the abstract
HbA1c
MD (95% CI)
Tirzepatide 15 mgvs Subcutaneous semaglutide 1.0 mg
−0.52(−0.96 to −0.08)
Tirzepatide 15 mgvs Oral semaglutide 14 mg
- 1.23(−1.64 to −0.81)
Further pooled results
| Outcome | MD (95% CI) | |
|---|---|---|
| Body weightTirzepatide 15 mgvs Subcutaneous semaglutide 1.0 mg | −5.07 (−8.28 to −1.86) | |
| Body weightTirzepatide 15 mgvs Oral semaglutide 14 mg | −6.84 (−8.97 to −4.71) | |
| −10−505Difference (linear scale) |
Semaglutide vs conventional GLP-1 RAs
- Both subcutaneous and oral semaglutide were more effective than conventional GLP-1 RAs (dulaglutide, liraglutide, lixisenatide)
Original publication
Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. Published 12 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →